Is using the QALY ethical when resources are extremely scarce? Symposium 23 January 2013 Pages: 2 - 2
Psychotherapy for subthreshold depression may save costs Non-clinical study 23 January 2013 Pages: 2 - 2
Darunavir/ritonavir dominates most other PI/ritonavir combinations Clinical study 23 January 2013 Pages: 6 - 6
Adjusting for health-related QOL does not appear to substantially affect cost per life year (LY) ratios for most cancer studies Non-clinical study 23 January 2013 Pages: 6 - 6
Literature supports capecitabine for breast and colorectal cancer News item 23 January 2013 Pages: 7 - 7
Sorafenib + best supportive care (BSC) is more cost effective than BSC alone Clinical study 23 January 2013 Pages: 7 - 7
UGT1A1 genotyping prior to high-dose irinotecan therapy is cost saving for certain patient groups Clinical study 23 January 2013 Pages: 8 - 8
The cost utility of pemetrexed as first-line therapy for advanced non-small cell lung cancer appears to be hindered by poor basal QOL Clinical study 23 January 2013 Pages: 8 - 8
NICE and SIGN have gained NHS Evidence's seal of approval to act as guideline developers News item 23 January 2013 Pages: 9 - 9
British consumers are predicted to pay £521 million for over-the-counter (OTC) cold/flu remedies Media release 23 January 2013 Pages: 9 - 9
Pazopanib has been added to the Clinical Practice Guidelines in Oncology for Kidney Cancer, following its US FDA approval last month Media release 23 January 2013 Pages: 9 - 9
Survey predicts low uptake of H1N1 vaccine in Hong Kong Clinical study 23 January 2013 Pages: 10 - 10
Postarrest hypothermia produces benefits that justify its costs Clinical study 23 January 2013 Pages: 10 - 10
Retail clinics offer lower costs, similar quality of care Clinical study 23 January 2013 Pages: 11 - 11
The cost utility of adjuvant trastuzumab therapy for breast cancer appears more favourable in a Canadian population-based cohort Clinical study 23 January 2013 Pages: 11 - 11
Evidence-based guidelines for immunisation have been published by an Expert Panel of the Infectious Diseases Society of America (IDSA) Guideline 23 January 2013 Pages: 12 - 12
Risedronic-acid: more cost effective with wider application Clinical study 23 January 2013 Pages: 12 - 12
It can be important to include clinical variables not found in claims data when carrying out propensity score matching Clinical study 23 January 2013 Pages: 13 - 13
Fewer patients have forgone medication or basic needs because of drug costs since Medicare Part D was implemented in 2006 Clinical study 23 January 2013 Pages: 13 - 13
Interscalene brachial plexus blockade (ISB) appears to be cost effective versus general anaesthesia for arthroscopic shoulder surgery Clinical study 23 January 2013 Pages: 13 - 13
A nurse-led telephone follow-up accompanied by educational programme appears to be the most cost-effective follow-up strategy Clinical study 23 January 2013 Pages: 13 - 13
Diabetes: self monitoring 'cost effective' in Bangladesh Clinical study 23 January 2013 Pages: 13 - 13
Economic analyses of aromatase inhibitors that are sponsored by pharmaceutical companies are less likely to report unfavourable results Non-clinical study 23 January 2013 Pages: 13 - 13
Specialty pharmacy management is associated with greater compliance to rheumatoid arthritis (RA) medications Clinical study 23 January 2013 Pages: 14 - 14
Erbitux [cetuximab] is to be funded by the Ontario Government as a therapy for metastatic colorectal cancer Media release 23 January 2013 Pages: 14 - 14
The position of the Australian Pharmaceutical Benefit Scheme (PBS) looks to be stable Media release 23 January 2013 Pages: 14 - 14
Biosimilars of tumour necrosis factor-α (TNF-α) inhibitors will erode $9.6 billion in brand sales Media release 23 January 2013 Pages: 14 - 14
Gastric cancer drug market to grow through targeted therapies Media release 23 January 2013 Pages: 14 - 14
Decision Resources predicts that the bipolar disorder drug market will decline by more than $US1 billion over the next decade Media release 23 January 2013 Pages: 14 - 14